NASDAQ$FATE
Fate Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter 2022 financial results and highlighted operational progress.
Fate Therapeutics reported $15.0 million in revenue for the third quarter of 2022, derived from collaborations with Janssen and ONO, and cash, cash equivalents and investments totaled $519.1 million as of September 30, 2022.
- FT596+R enrollment is ongoing in the three-dose escalation cohort for R/R BCL and community sites are being activated for investigation of FT596+R-CHOP in newly-diagnosed patients with aggressive BCL.
- Positive feedback was received from the FDA under FT516 RMAT designation for derivation of a clonal engineered master iPSC bank and for potential registrational study design.
- Preclinical data of FT555, a GPRC5D-targeted CAR NK cell product candidate for R/R MM under the Janssen collaboration, will be presented at ASH, and Janssen has exercised its commercial option for an additional product candidate targeting an undisclosed hematologic malignancy antigen.
- 14 abstracts were selected for presentation at ASH, including interim Phase 1 dose-escalation data of FT576 for R/R MM and of FT819 for R/R BCL, and 12 abstracts were selected for presentation at SITC, including interim Phase 1 dose-escalation data of FT536 and FT538 for advanced solid tumors.
Headline financials
Revenue & EPS history
Fate Therapeutics · Revenue · Quarterly
$15M
Revenue by segment
Fate Therapeutics · $15M total across 1 segment · Q3 2022
- Collaboration Revenue$15M+5.6%100.0%
Forward guidance
The Company expects to submit an IND application for the product candidate under the collaboration during the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+19.0%
Q2 2016
Best reaction
-15.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | -22.8% | -8.5% | |
| Q4 2025 | +6.1% | -7.4% | -20.9% | |
| Q3 2025 | -2.1% | +6.1% | +16.2% | |
| Q1 2025 | -3.7% | +22.0% | +27.0% | |
| Q4 2024 | -1.6% | +2.2% | +20.7% | |
| Q3 2024 | -15.2% | -21.1% | -24.6% | |
| Q2 2024 | -1.8% | +2.1% | +12.3% | |
| Q1 2024 | +10.3% | +14.1% | -0.5% | |
| Q4 2023 | +7.2% | +11.2% | +5.5% | |
| Q3 2023 | -7.8% | -13.9% | -3.0% | |
| Q2 2023 | -4.2% | -13.0% | -30.4% | |
| Q1 2023 | +4.2% | -7.9% | -11.3% | |
| Q4 2022 | +1.3% | +1.7% | -11.8% | |
| Q3 2022 | -1.0% | -2.1% | +4.3% | |
| Q2 2022 | +6.3% | +11.5% | -12.8% | |
| Q1 2022 | -5.5% | -22.3% | -17.8% | |
| Q4 2021 | -1.5% | -7.0% | +14.1% | |
| Q3 2021 | +1.7% | +1.1% | -20.5% | |
| Q2 2021 | +14.8% | +15.0% | -12.3% | |
| Q1 2021 | -4.0% | -5.0% | -8.7% | |
| Q4 2020 | -9.6% | +1.2% | -24.4% | |
| Q3 2020 | -3.1% | +5.6% | +22.0% | |
| Q2 2020 | +2.5% | +10.4% | -4.6% | |
| Q1 2020 | -0.3% | -1.4% | +14.4% | |
| Q4 2019 | -3.3% | +0.9% | -30.8% | |
| Q3 2019 | -12.5% | -4.6% | -11.3% | |
| Q2 2019 | -3.8% | -2.9% | -6.0% | |
| Q1 2019 | -7.8% | -2.6% | -1.1% | |
| Q4 2018 | -3.1% | -0.1% | +12.0% | |
| Q3 2018 | +18.4% | +16.5% | +23.3% | |
| Q2 2018 | +15.6% | +17.6% | +28.6% | |
| Q1 2018 | -14.0% | -10.4% | +8.7% | |
| Q4 2017 | -1.6% | -0.8% | -20.8% | |
| Q3 2017 | -1.0% | +4.0% | -8.0% | |
| Q2 2017 | +6.7% | -3.4% | +44.6% | |
| Q1 2017 | +1.2% | -1.0% | -24.7% | |
| Q4 2016 | +5.5% | -3.4% | -10.4% | |
| Q3 2016 | +10.8% | +50.3% | +53.3% | |
| Q2 2016 | +19.0% | +21.3% | +20.9% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +15.9% | — | — | |
| Q2 2015 | -5.1% | — | — | |
| Q1 2015 | -0.3% | — | — | |
| Q4 2014 | +3.9% | — | — | |
| Q3 2013 | +1.9% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro